Chia‐Yen Dai

机构：Kaohsiung Medical University, Kaohsiung Medical University Chung-Ho Memorial Hospital · ORCID：0000-0003-2296-3054

发表论文 583 篇 · 总被引 10682 次 · h-index 53

代表论文

• Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial (2025 · Nature Medicine · 被引 12)
• Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis (2025 · Hepatology · 被引 6)
• Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication (2025 · Alimentary Pharmacology & Therapeutics · 被引 5)
• Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL ‐B Study (2025 · Alimentary Pharmacology & Therapeutics · 被引 5)
• Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma (2025 · Clinical and Molecular Hepatology · 被引 4)
• Dynamics of Cardiometabolic Risk Factors Are Linked to the Risk of Hypertension and Diabetes in MASLD (2025 · The Kaohsiung Journal of Medical Sciences · 被引 4)